Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Chronic spontaneous urticaria
Other

Chronic spontaneous urticaria

Tracked across 1 events · 22 articles · First seen Jun 07, 2026 · Last active Jun 08, 2026

Sentiment
0
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
6 0
Business
Roche, Nurix Therapeutics $2.3B Bexobrutideg Deal
Roche has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg (also known as NX-5948), an investigational Bruton's Tyrosine Kinase (BTK) degrader. Roche will pay Nurix Therapeutics an…
Impact: Chronic spontaneous urticaria (CSU) is an immunological condition that bexobrutideg is planned to be developed for, with Phase 2 trials. This expands the potential therapeutic reach of the drug beyond oncology.
Jun 07, 2026 · 22 articles
NEWSDESK
Track Chronic spontaneous urticaria live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.